Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02088112
Title MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Gefitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.